Phage therapy in the Covid-19 era: Advantages over antibiotics

Barr, 2013, Bacteriophage adhering to mucus provide a non-host-derived immunity, Proc. Natl. Acad. Sci. U. S. A., 110, 10771, 10.1073/pnas.1305923110 Batinovic, 2019, Bacteriophages in Nat. Artificial Environ. Pathog. Basel Switz., 8, 100 Becattini, 2016, Antibiotic-induced changes in the intestinal microbiota and disease, Trends Mol. Med., 22, 458, 10.1016/j.molmed.2016.04.003 Belkaid, 2014, Role of the microbiota in immunity and inflammation, Cell, 157, 121, 10.1016/j.cell.2014.03.011 Beović, 2020, Antibiotic use in patients with COVID-19: a 'snapshot' infectious diseases international research initiative (ID-IRI) survey, J. Antimicrob. Chemother., 10.1093/jac/dkaa326 Berryhill, 2021, Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections, Proc. Natl. Acad. Sci., 118, 10.1073/pnas.2008007118 Bertozzi Silva, 2016, Host receptors for bacteriophage adsorption, FEMS Microbiol. Lett., 363, 10.1093/femsle/fnw002 Bhatt, 2021, Risk factors and outcomes of hospitalized patients with severe coronavirus disease 2019 (COVID-19) and secondary bloodstream infections: a multicenter case-control study, Clin. Infect. Dis., 72, 10.1093/cid/ciaa1748 Bradley, 2019, Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection, Cell Rep., 28, 10.1016/j.celrep.2019.05.105 Burmeister, 2020, Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance, Proc. Natl. Acad. Sci., 117, 11207, 10.1073/pnas.1919888117 Cafora, 2020, Phages as immunomodulators and their promising use as anti-inflammatory agents in a cftr loss-of-function zebrafish model, J. Cyst. Fibros. Chan, 2016, Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa, Sci. Rep., 6, 26717, 10.1038/srep26717 Chan, 2021, Bacteriophage therapy for infections in CF, Pediatr. Pulmonol., 56, 10.1002/ppul.25190 Chang, 2018, Phage therapy for respiratory infections, Adv. Drug Deliv. Rev., 133, 76, 10.1016/j.addr.2018.08.001 Chen, 2021, Modulation of gut microbiota for the prevention and treatment of COVID-19, J. Clin. Med., 10, 2903, 10.3390/jcm10132903 Cohan, 2020, Broadscale phage therapy is unlikely to select for widespread evolution of bacterial resistance to virus infection, Virus Evol., 6, 10.1093/ve/veaa060 Cohan, 2020, Broadscale phage therapy is unlikely to select for widespread evolution of bacterial resistance to virus infection, Virus Evol, 6, 10.1093/ve/veaa060 Comber, 2020, COVID-19, antibiotics and one health: A UK environmental risk assessment, J. Antimicrob. Chemother., 75, 3411, 10.1093/jac/dkaa338 Cong, 2021, Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: a scoping review, Antibiotics, 10, 745, 10.3390/antibiotics10060745 Dang, 2019, Microbes, metabolites, and the gut–lung axis, Mucosal Immunol., 12, 843, 10.1038/s41385-019-0160-6 Dhar, 2020, Gut microbiota and Covid-19- possible link and implications, Virus Res., 285, 10.1016/j.virusres.2020.198018 Dolgin, 2021, The race for antiviral drugs to beat COVID — and the next pandemic, Nature, 592, 340, 10.1038/d41586-021-00958-4 Fernández, 2019, The perfect bacteriophage for therapeutic applications—a quick guide, Antibiotics, 8, 10.3390/antibiotics8030126 Ferriol-González, 2020, Phages for biofilm removal, Antibiotics, 9, 268, 10.3390/antibiotics9050268 Founou, 2021, The COVID-19 pandemic: a threat to antimicrobial resistance containment, Future Sci. OA, 7, 10.2144/fsoa-2021-0012 García, 2020, Immune response, inflammation, and the clinical spectrum of COVID-19, Front. Immunol., 11, 10.3389/fimmu.2020.01441 Gavriatopoulou, 2020, Organ-specific manifestations of COVID-19 infection, Clin. Exp. Med., 20, 493, 10.1007/s10238-020-00648-x Górski, 2019, Perspectives of phage therapy in non-bacterial infections, Front. Microbiol., 9, 10.3389/fmicb.2018.03306 Górski, 2021, Bacteriophage interactions with epithelial cells: therapeutic implications, Front. Microbiol., 0 Górski, 2006, Bacteriophages and transplantation tolerance, Transpl. Proc., 38, 331, 10.1016/j.transproceed.2005.12.073 Górski, 2016, Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases, Front. Microbiol., 7, 10.3389/fmicb.2016.01515 Grau, 2021, Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic, Antibiotics, 10, 132, 10.3390/antibiotics10020132 Gu Liu, 2020, Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry, MBio, 11, 10.1128/mBio.01462-20 Hall, 2017, Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria, FEMS Microbiol. Rev., 41, 276, 10.1093/femsre/fux010 Harper, 2014, Bacteriophages and biofilms, Antibiot. Basel Switz., 3, 270 Hashimoto, 2012, ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation, Nature, 487, 477, 10.1038/nature11228 Hill, 2000, Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis, Am. J. Med., 109, 288, 10.1016/S0002-9343(00)00507-6 Huffnagle, 2017, The respiratory tract microbiome and lung inflammation: a two-way street, Mucosal Immunol., 10, 299, 10.1038/mi.2016.108 Jolobe, 2021, A more appropriate use of antibiotics in COVID-19 infection, QJM Int. J. Med. Ke, 2019, Phage Therapy: a renewed approach to combat antibiotic-resistant bacteria, Cell Host Microbe, 25 Keely, 2012, Pulmonary-intestinal cross-talk in mucosal inflammatory disease, Mucosal Immunol., 5, 7, 10.1038/mi.2011.55 Koester, 2021, Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome, PLoS ONE, 16, 10.1371/journal.pone.0248730 Kumar, 2021, Antidrug resistance in the Indian ambient waters of Ahmedabad during the COVID-19 pandemic, J. Hazard. Mater., 416, 10.1016/j.jhazmat.2021.126125 Langford, 2021, Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis, Clin. Microbiol. Infect., 27, 520, 10.1016/j.cmi.2020.12.018 Langford, 2020, Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis, Clin. Microbiol. Infect., 10.1016/j.cmi.2020.07.016 Levy, 2017, Dysbiosis and the immune system, Nat. Rev. Immunol., 17, 219, 10.1038/nri.2017.7 Li, 2018, The microbiome and autoimmunity: a paradigm from the gut–liver axis, Cell. Mol. Immunol., 15, 595, 10.1038/cmi.2018.7 Liu, 2021, The safety and toxicity of phage therapy: a review of animal and clinical studies, Viruses, 13, 1268, 10.3390/v13071268 Livermore, 2021, Antibiotic resistance during and beyond COVID-19, JAC-Antimicrob. Resist., 3, 10.1093/jacamr/dlab052 Loc-Carrillo, 2011, Pros and cons of phage therapy, Bacteriophage, 1, 111, 10.4161/bact.1.2.14590 Maslov, 2017, Population cycles and species diversity in dynamic kill-the-winner model of microbial ecosystems, Sci. Rep., 7, 39642, 10.1038/srep39642 Miedzybrodzki, 2009, A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses, Clin. Exp. Med., 9, 303, 10.1007/s10238-009-0044-2 Miernikiewicz, 2016, T4 phage tail adhesin Gp12 counteracts LPS-induced inflammation in vivo, Front. Microbiol., 7, 10.3389/fmicb.2016.01112 Munita, 2016, Mechanisms of antibiotic resistance, Microbiol. Spectr., 4, 10.1128/microbiolspec.VMBF-0016-2015 Nilsson, 2019, Pharmacological limitations of phage therapy, Ups. J. Med. Sci., 124, 218, 10.1080/03009734.2019.1688433 Pabary, 2016, Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung, Antimicrob. Agents Chemother., 60, 744, 10.1128/AAC.01426-15 Peiris, 2021, Pathological findings in organs and tissues of patients with COVID-19: a systematic review, PLoS ONE, 16, 10.1371/journal.pone.0250708 Przybylski, 2015, T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro, Future Microbiol., 10, 453, 10.2217/fmb.14.147 Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R., Salem, R., 2020. The COVID-19 cytokine storm; what we know so far 11. https://doi.org/10.3389/fimmu.2020.01446. Rakhuba, 2010, Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell, Pol J. Microbiol., 59, 145, 10.33073/pjm-2010-023 Richman, 2016, Antiviral Therapy, Viral Pathog., 271, 10.1016/B978-0-12-800964-2.00020-3 Rizzo, 2013, Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: a review, Sci. Total Environ., 447, 345, 10.1016/j.scitotenv.2013.01.032 Rosenblatt-Farrell, 2009, The landscape of antibiotic resistance, Environ. Health Perspect., 117, 10.1289/ehp.117-a244 Steed, 2017, The microbial metabolite desaminotyrosine protects from influenza through type I interferon, Science, 357, 498, 10.1126/science.aam5336 Sulakvelidze, 2001, Bacteriophage Therapy, Antimicrob. Agents Chemother., 45, 649, 10.1128/AAC.45.3.649-659.2001 Sulis, 2021, Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: an interrupted time series analysis, PLOS Med., 18, 10.1371/journal.pmed.1003682 Sun, L., Zhang, X., Zhang, Y., Zheng, K., Xiang, Q., Chen, N., Chen, Z., Zhang, N., Zhu, J., He, Q., 2019. Antibiotic-induced disruption of gut microbiota alters local metabolomes and immune responses 9. https://doi.org/10.3389/fcimb.2019.00099. Suttle, 2007, Marine viruses — major players in the global ecosystem, Nat. Rev. Microbiol., 5, 801, 10.1038/nrmicro1750 Taati Moghadam, 2020, How phages overcome the challenges of drug resistant bacteria in clinical infections, Infect. Drug Resist., 13, 45, 10.2147/IDR.S234353 Tagliabue, 2018, Changing priorities in vaccinology: antibiotic resistance moving to the top, Front. Immunol., 9, 10.3389/fimmu.2018.01068 Trougakos, 2021, Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications, J. Biomed. Sci., 28, 9, 10.1186/s12929-020-00703-5 Van Belleghem, 2018, Interactions between bacteriophage, bacteria, and the mammalian immune system, Viruses, 11, 10.3390/v11010010 Vandamme, 2019, A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy!, J. Chem. Technol. Biotechnol., 94, 323, 10.1002/jctb.5810 Weyand, 2016, Aging of the immune system. Mechanisms and therapeutic targets, Ann. Am. Thorac. Soc., 13, 10.1513/AnnalsATS.201602-095AW Wittebole, 2014, A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens, Virulence, 5, 226, 10.4161/viru.25991 Wojewodzic, 2020, Bacteriophages could be a potential game changer in the trajectory of coronavirus disease (COVID-19), PHAGE, 1, 60, 10.1089/phage.2020.0014 Wu, 2021, Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients, Emerg. Microbes Infect., 10, 612, 10.1080/22221751.2021.1902754 Yacouba, 2021, Repurposing of antibiotics for clinical management of COVID-19: a narrative review, Ann. Clin. Microbiol. Antimicrob., 20, 37, 10.1186/s12941-021-00444-9 Yamamoto, 2021, The human microbiome and COVID-19: a systematic review, PLoS ONE, 16, 10.1371/journal.pone.0253293 Yamamoto, 2021, The human microbiome and COVID-19: a systematic review, PLoS ONE, 16, 10.1371/journal.pone.0253293 Zhang, 2020, Origin and evolution of the 2019 novel coronavirus, Clin. Infect. Dis., 71, 882, 10.1093/cid/ciaa112 Zuo, 2020, Alterations in gut microbiota of patients with COVID-19 during time of hospitalization, Gastroenterology, 159